Eli Lilly announced that its next-generation obesity drug, retatrutide, has cleared a critical late-stage trial, demonstrating substantial weight loss efficacy. In the trial, patients receiving the highest dose lost an average of 28.3% of their weight, equating to 70.3 pounds over 80 weeks, compared to just 2.2% in the placebo group.
Notably, around 45% of the 2,500 participants achieved a weight loss of 30% or more. This level of weight loss is significant as it has typically only been associated with bariatric surgery, according to Dan Skovronsky, Lilly's chief scientific and product officer. The drug also showed promise for patients with a BMI of 35 or higher, who lost an average of 30.3% of their weight over 104 weeks.
While some gastrointestinal side effects were reported, they were consistent with previous trials and did not deter the overall positive results. Analysts had anticipated that retatrutide would outperform Lilly's existing weight loss drug, Zepbound, which has shown weight loss of around 20% to 22%.
With projections estimating retatrutide could generate $3.8 billion in sales by 2030, Lilly is positioning it as a key component of its obesity portfolio, which includes Zepbound and the newly launched Foundayo. The competitive landscape is heating up, as Novo Nordisk, which holds a significant market share, is also developing similar treatments.
As the obesity and diabetes drug market is expected to reach around $100 billion by the 2030s, Lilly's advancements with retatrutide could solidify its leading position in this lucrative sector